Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history

Abstract Background There is no international consensus up to which age women with a diagnosis of triple-negative breast cancer (TNBC) and no family history of breast or ovarian cancer should be offered genetic testing for germline BRCA1 and BRCA2 (gBRCA) mutations. Here, we explored the association...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Christoph Engel, Kerstin Rhiem, Eric Hahnen, Sibylle Loibl, Karsten E. Weber, Sabine Seiler, Silke Zachariae, Jan Hauke, Barbara Wappenschmidt, Anke Waha, Britta Blümcke, Marion Kiechle, Alfons Meindl, Dieter Niederacher, Claus R. Bartram, Dorothee Speiser, Brigitte Schlegelberger, Norbert Arnold, Peter Wieacker, Elena Leinert, Andrea Gehrig, Susanne Briest, Karin Kast, Olaf Riess, Günter Emons, Bernhard H. F. Weber, Jutta Engel, Rita K. Schmutzler, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC)
Format:	Article
Language:	English
Published:	BMC 2018-03-01
Subjects:	Hereditary breast and ovarian cancer BRCA1 BRCA2 Triple-negative breast cancer
Online Access:	http://link.springer.com/article/10.1186/s12885-018-4029-y